Literature DB >> 22934661

Smoking and socio-economic status may affect myasthenia gravis.

A H Maniaol1, M Boldingh1, C Brunborg2, H F Harbo1,3, C M E Tallaksen1,3.   

Abstract

BACKGROUND AND
PURPOSE: The influence of environmental factors in myasthenia gravis (MG) is unknown. The aim of this cross-sectional population-based study was to investigate if smoking and socio-economic status (SES) were associated with MG in the Norwegian population.
METHODS: Subjects were 491 MG patients identified in Norway at the time of the study (point prevalence 12.7/100 000). A questionnaire covering smoking habits and markers of SES (education and occupation) was mailed to all patients. Population data were obtained from Statistics Norway.
RESULTS: A total of 375 (76.6%) patients completed the questionnaire (236 women, mean age 59 ± 18 years), of which 193 reported to be early onset MG (EOMG, onset ≤40 years, 155 women). Compared with the general population, current smoking was more prevalent amongst MG patients [risk ratio (RR) 1.5; 95% confidence interval (CI) 1.1-1.9], most of whom had EOMG. Female MG patients had higher education compared with the general population (RR 4.5; 95% CI 3.2-6.2). Male MG patients were similar to the general population regarding both education and occupation, except for a subset of late onset MG who had shorter education (RR 1.9; 95% CI 1.1-3.2) and had worked in crafts and related trades. About half of working age MG patients received disability pension, a finding significantly related to low educational level and a more severe disease course (P < 0.001).
CONCLUSION: This is the first report indicating that smoking and SES may affect MG. Further studies investigating their role as potential risk factors are warranted.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Year:  2012        PMID: 22934661     DOI: 10.1111/j.1468-1331.2012.03843.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

1.  The α4 nicotinic receptor promotes CD4+ T-cell proliferation and a helper T-cell immune response.

Authors:  Jacob C Nordman; Pretal Muldoon; Sarah Clark; M Imad Damaj; Nadine Kabbani
Journal:  Mol Pharmacol       Date:  2013-10-09       Impact factor: 4.436

2.  Increased risk for clinical onset of myasthenia gravis during the postpartum period.

Authors:  Marion I Boldingh; Angelina H Maniaol; Cathrine Brunborg; Harald Weedon-Fekjær; Jan J G M Verschuuren; Chantal M E Tallaksen
Journal:  Neurology       Date:  2016-10-21       Impact factor: 9.910

3.  Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.

Authors:  Sean M Gratton; Angela M Herro; William J Feuer; Byron L Lam
Journal:  J Neuroophthalmol       Date:  2016-03       Impact factor: 3.042

4.  Association of Smoking and Generalized Manifestations of Myasthenia Gravis.

Authors:  Yusei Miyazaki; Masaaki Niino; Ken Sakushima; Eri Takahashi; Ryoji Naganuma; Itaru Amino; Sachiko Akimoto; Naoya Minami; Ichiro Yabe; Seiji Kikuchi
Journal:  Intern Med       Date:  2021-11-06       Impact factor: 1.282

5.  Patient-Reported Symptom Severity in a Nationwide Myasthenia Gravis Cohort: Cross-sectional Analysis of the Swedish GEMG Study.

Authors:  Malin Petersson; Amalia Feresiadou; Daniel Jons; Andreea Ilinca; Fredrik Lundin; Rune Johansson; Anna Budzianowska; Anna-Karin Roos; Viktor Kågström; Martin Gunnarsson; Peter Sundström; Fredrik Piehl; Susanna Brauner
Journal:  Neurology       Date:  2021-08-10       Impact factor: 9.910

6.  An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts.

Authors:  M I Boldingh; L Dekker; A H Maniaol; C Brunborg; A F Lipka; E H Niks; J J G M Verschuuren; C M E Tallaksen
Journal:  Health Qual Life Outcomes       Date:  2015-08-01       Impact factor: 3.186

7.  Familial aggregation of myasthenia gravis in affected families: a population-based study.

Authors:  Fu-Chao Liu; Chang-Fu Kuo; Lai-Chu See; Hsin-I Tsai; Huang-Ping Yu
Journal:  Clin Epidemiol       Date:  2017-11-02       Impact factor: 4.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.